Kymera’s stock rises after derma investigation expands; Ligand buys Apeiron

Plus, news about AEON Biopharma, Moderna and Mitsubishi Tanabe:

Sanofi expands dermatology trials: Kymera Therapeutics said that expanding the Phase 2 hidradenitis suppurativa and atopic dermatitis studies will “more rapidly progress” the candidate, dubbed KT-474, into pivotal studies. Sanofi and Kymera are collaborating on the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks